AlAbbasi Omar, Magliyah Moustafa S, Ahad Muhammad
Cornea and Anterior Segment Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Ophthalmology Department, Ohud Hospital, Madinah, Saudi Arabia.
Am J Ophthalmol Case Rep. 2021 Jan 6;21:101009. doi: 10.1016/j.ajoc.2020.101009. eCollection 2021 Mar.
To report long term results of two cases treated with topical cyclosporin A 1% for keratitis associated with autoimmune polyglandular syndrome (APS1).
A 25-year-old male and a 17-year-old female were referred from endocrinology as APS1-related autoimmune keratitis. Extended-duration treatment with topical cyclosporin A (CsA) 1% was used for 24 and 18 months, respectively. The first patient had improved best-corrected visual acuity (BCVA) from 20/200 and 20/300 in right and left eye to 20/60 in both eyes with markedly improved corneal opacification, while the second patient had improved BCVA from 20/400 and 20/300 in right and left eye to 20/160 in both eyes with persistent central stromal scarring in the right eye and discrete areas of stromal scarring in the left eye.
Long-term topical CsA 1% offers a valuable option for treatment of APS1-related autoimmune keratitis.
报告两例使用1%环孢素A局部治疗与自身免疫性多腺体综合征（APS1）相关的角膜炎的长期结果。
一名25岁男性和一名17岁女性因APS1相关的自身免疫性角膜炎被内分泌科转诊。分别使用1%环孢素A（CsA）进行了24个月和18个月的长期局部治疗。首例患者右眼和左眼的最佳矫正视力（BCVA）从20/200和20/300提高到双眼20/60，角膜混浊明显改善；而第二例患者右眼和左眼的BCVA从20/400和20/300提高到双眼20/160，右眼有持续性中央基质瘢痕，左眼有散在的基质瘢痕区域。
长期局部使用1% CsA为治疗APS1相关的自身免疫性角膜炎提供了一种有价值的选择。
